San Diego Digital Chemistry Lunch & Workshop

Dr. Zhe Nie is the Executive Director of Medicinal Chemistry at Schrödinger’s Therapeutic Group. She has been leading multiple wholly owned and partnered drug discovery programs at Schrödinger. Most recently, she led Schrödinger’s MALT1 discovery project team, successfully developed the small molecule drug SGR-1505 (Schrödinger’s first internal clinical asset currently in Ph1) applying Schrödinger’s computational platform. It took less than two years from the start of the project to the selection of the clinical candidate. She also led the DLK collaboration project with Takeda Pharmaceuticals which discovered a potent, selective, and brain-penetrate DLK inhibitor as a promising preclinical candidate for the treatment of neurodegenerative diseases using Schrödinger’s computational platform. She has extensive experiences in applying advanced computational tools to assist in the design of small molecule drug candidates. She previously worked at Takeda, Celgene and Quanticel Pharmaceuticals (acquired by Celgene), led and contributed to advancing multiple small molecule drugs to the clinics including TAK-960, TAK-659 and CC-90011.

Dr. Morgan Lawrenz is a computational chemist and has been with STG for 5 years, based in San Diego. Before joining Schrodinger, Dr. Lawrenz worked on molecular glue compounds to target protein-protein interactions at Nurix therapeutics in San Francisco. In STG, She enjoys leveraging the Schrödinger technology platform and is actively working to expand it. Dr. Lawrenz interfaces with software developers to bring new tools to bear on difficult problems in drug discovery projects.